- Home
- ONFO vs BTAI Comparison
ONFO vs BTAI Comparison
Compare ONFO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- BTAI
- Stock Information
- Founded
- ONFO 2018
- BTAI 2017
- Country
- ONFO United States
- BTAI United States
- Employees
- ONFO N/A
- BTAI N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- BTAI Health Care
- Exchange
- ONFO Nasdaq
- BTAI Nasdaq
- Market Cap
- ONFO 6.2M
- BTAI 7.2M
- IPO Year
- ONFO 2022
- BTAI 2018
- Fundamental
- Price
- ONFO $0.93
- BTAI $1.99
- Analyst Decision
- ONFO
- BTAI Buy
- Analyst Count
- ONFO 0
- BTAI 5
- Target Price
- ONFO N/A
- BTAI $42.60
- AVG Volume (30 Days)
- ONFO 31.1K
- BTAI 1.2M
- Earning Date
- ONFO 05-20-2025
- BTAI 03-27-2025
- Dividend Yield
- ONFO N/A
- BTAI N/A
- EPS Growth
- ONFO N/A
- BTAI N/A
- EPS
- ONFO N/A
- BTAI N/A
- Revenue
- ONFO $6,590,171.00
- BTAI $2,266,000.00
- Revenue This Year
- ONFO $133.59
- BTAI $105.36
- Revenue Next Year
- ONFO N/A
- BTAI $46.93
- P/E Ratio
- ONFO N/A
- BTAI N/A
- Revenue Growth
- ONFO 29.25
- BTAI 64.20
- 52 Week Low
- ONFO $0.39
- BTAI $1.72
- 52 Week High
- ONFO $1.88
- BTAI $49.58
- Technical
- Relative Strength Index (RSI)
- ONFO 40.53
- BTAI 39.93
- Support Level
- ONFO $0.61
- BTAI $1.76
- Resistance Level
- ONFO $1.38
- BTAI $2.11
- Average True Range (ATR)
- ONFO 0.11
- BTAI 0.28
- MACD
- ONFO -0.03
- BTAI 0.02
- Stochastic Oscillator
- ONFO 41.34
- BTAI 16.98
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.